Targeted Immune Therapy: The Next Alzheimer's Treatment?

the MPR take:

Targeted stimulation of the immune system in mice has led to the removal of amyloid plaque formation, (a known marker of Alzheimer’s disease), according to researchers at NYU Langone Medical Center. Dementia-prone mice given monthly injections of a type B, CpG, oligodeoxynucleotide, which binds to Toll-like receptor 9, showed a 50-70% reduction in amyloid plaque formation vs. controls. Amyloid beta reductions were nearly identical for mice treated early, at age 7 months, and before disease onset vs. mice treated at age 11 months with mild dementia. Dementia-associated brain inflammation was reduced by 50% in the mice treated with the immunotherapy. Human clinical trials could begin within a year if additional animal testing is successful.

Targeted immune booster removes toxic proteins in mouse model of Alzheimer's disease
Targeted Immune Therapy: The Next Alzheimer's Treatment?

(NYU Langone Medical Center / New York University School of Medicine) Alzheimer's disease experts at NYU Langone Medical Center and elsewhere are reporting success in specifically harnessing a mouse's immune system to attack and remove the buildup of toxic proteins in the brain that are markers of the deadly neurodegenerative disease.